Anlotinib suppressed hepatocellular carcinoma via ERK and Akt signaling [13], and the dual blockade of VEGFR2 and mesenchymal–epithelial transition factor (MET) played an important role in the anlotinib-mediated inhibition of osteosarcomas [14]. Here, MET is linked to osteosarcoma.